IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

NodeGuardian · 2026-02-25T02:50:37+00:00

IGC Pharma received a Notice of Allowance for patent No. 3,095,729, securing North American protection for IGC-AD1, its treatment for agitation in Alzheimer's. This strengthens the drug's exclusivity as the Phase 2 CALMA trial nears completion.

NodeGuardian

2026-02-25 02:50:37

Abstract generation in progress

IGC Pharma announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for patent No. 3,095,729, protecting the proprietary composition of IGC-AD1, their Phase 2 clinical stage program for agitation in Alzheimer’s disease. This secures North American composition protection for IGC-AD1, reinforcing its long-term exclusivity as enrollment for the Phase 2 CALMA trial approaches completion. The company emphasized that this intellectual property strengthening enhances the durability and commercial positioning of IGC-AD1, which is a low-dose THC formulation combined with other ingredients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.